Professor Yarger has an active research group in amorphous pharmaceuticals and the physical chemistry of active pharmaceutical ingredients (API’s). There has been a recent national interest in cannabinoids and API’s related to the hemp (cannabis) plant. Below is some general ‘News’ in this area.
Characterizing Pharmaceutical Formulations Using Solid-State NMR Spectroscopy
Advanced analytical techniques can provide unique insight into the composition and properties of pharmaceutical formulations. In particular, both structural and mobility information can be obtained about the formulations, but the challenge is to relate that information to functional properties such as physical and chemical stability, dissolution rate, and processing parameters. Solid-state NMR spectroscopy is a powerful technique to study polymorphism, form changes upon processing, the presence of small amounts of amorphous drug in crystalline solids (for chemical/physical stability), and small amounts of crystalline drug in amorphous solid dispersions (for physical stability). Solid-state NMR relaxation times have been used to measure particle size, crystal defects, and chemical impurities in crystalline materials. In addition, relaxation times have been used to determine the phase separation of amorphous formulations. Finally, mobility, phase separation, and microenvironment acidity has been studied to predict stability in large-molecule formulations.
Cannabis/Hemp Web-Site and Recent Articles:
- Complex Patterns of Cannabinoid Alkyl Side-Chain Inheritance in Cannabis
- Open Access PDF – Cannabis_Alkyl_SideChain_SR2019.pdf (see below)
- Characterization of By-Products from Commercial Cannabidiol Production
- Glucose metabolism links astroglial mitochondria to cannabinoid effects
- Synthetic Access to Cannabidiol and Analogs as Active Pharmaceutical Ingredients
- NPR – Does CBD Oil Work for Arthritis Pain?
- Cannabis Vaporizer – How to Take Steps to Overcome a Crisis
- Uncovering the Hidden Antibiotic Potential of Cannabis
- Media reports focus on treatments involving opioids and cannabis for chronic pain
- Hemp Farmers Struggle to Find Success in the Green Rush.
- Medical Cannabis Shows Promise in Reducing Opioid Misuse, Finds New Review.
- Cannabis Flowers with Mushrooms Shaped Hairs.
- Analysis of impurities in cannabidiol from Hemp.
- Marijuana Fed Pigs are Bigger and Tastier Without Antibiotics or Hormones
May 2020 | Argonne National Labs – APS
Feb 2020 | Chemical and Engineering News
Dec. 2019 – Feb. 2020 | ASU, Vext and BioSciTech
Notice Number: NOT-AT-20-002
Release Date: December 13, 2019
First Available Due Date: February 05, 2020
Expiration Date: January 08, 2022
National Center for Complementary and Integrative Health (NCCIH)
Through this Notice of Special Interest (NOSI), the National Center for Complementary and Integrative Health (NCCIH) announces its interest in supporting research grant applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and/or nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene, ß-caryophyllene, Limonene, a-terpineol, Linalool, a-phellandrene, a-pinene, ß-pinene, ?-terpinene, and a -humulene. Through this NOSI, NCCIH intends to support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the input of minor cannabinoids and terpenes on mechanisms underlying analgesia or pain relief.
The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to pain relief and functional restoration may be very broad encompassing different pain conditions. This NOSI encourages interdisciplinary collaborations among experts from multiple fields, such as pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, or others in relevant areas of inquiry.